Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Search
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
Cat care interview veterinarian Dr Susan Little
World-renowned feline healthcare specialist Dr. Susan Little shares her thoughts on latest trends in cat care.
A beginner’s guide to fighting off cat parasites
Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Health Equity: No distance is too far
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371